Short-Course Treatment Regimen of Indian Visceral Leishmaniasis with an Indian Liposomal Amphotericin B Preparation (Fungisome™)
India bears the burden of about half of global visceral leishmaniasis (VL) cases with emerging problems of stibanate resistance. Liposomal preparations have improved treatment outcome through shorter duration of therapy and lower toxicity compared with conventional amphotericin B. We report the effi...
Saved in:
Published in | The American journal of tropical medicine and hygiene Vol. 94; no. 1; pp. 93 - 98 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
The American Society of Tropical Medicine and Hygiene
01.01.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | India bears the burden of about half of global visceral leishmaniasis (VL) cases with emerging problems of stibanate resistance. Liposomal preparations have improved treatment outcome through shorter duration of therapy and lower toxicity compared with conventional amphotericin B. We report the efficacy of two short-course regimens of an Indian preparation of liposomal amphotericin B (Fungisome™) for VL caused by Leishmania donovani in India. An open-label, randomized, single-center comparative study was undertaken from 2008 to 2011, involving 120 treatment naive non-human immunodeficiency virus VL patients randomly allocated to two groups. Fungisome™ was given, in groups A (N = 60), 5 mg/kg daily for 2 days and B (N = 60), 7.5 mg/kg daily for 2 days, as intravenous infusion. Initial cure rate was 100% in both the groups after 1 month posttreatment. At 6 months after completion of treatment, definitive cure rate was group A 90% (54/60, 95% confidence interval (CI): 80.55-95.72%); group B: 100% (95% CI: 95.92-100%); (P = 0.027). No serious adverse events occurred in either group. The short-course, 2-day regimen of 15 mg/kg Fungisome™ infusion is easy to administer, effective, and safe for treatment of VL caused by L. donovani in India. |
---|---|
AbstractList | India bears the burden of about half of global visceral leishmaniasis (VL) cases with emerging problems of stibanate resistance. Liposomal preparations have improved treatment outcome through shorter duration of therapy and lower toxicity compared with conventional amphotericin B. We report the efficacy of two short-course regimens of an Indian preparation of liposomal amphotericin B (Fungisome™) for VL caused by
Leishmania donovani
in India. An open-label, randomized, single-center comparative study was undertaken from 2008 to 2011, involving 120 treatment naive non–human immunodeficiency virus VL patients randomly allocated to two groups. Fungisome™ was given, in groups A (
N
= 60), 5 mg/kg daily for 2 days and B (
N
= 60), 7.5 mg/kg daily for 2 days, as intravenous infusion. Initial cure rate was 100% in both the groups after 1 month posttreatment. At 6 months after completion of treatment, definitive cure rate was group A 90% (54/60, 95% confidence interval (CI): 80.55–95.72%); group B: 100% (95% CI: 95.92–100%); (
P
= 0.027). No serious adverse events occurred in either group. The short-course, 2-day regimen of 15 mg/kg Fungisome™ infusion is easy to administer, effective, and safe for treatment of VL caused by
L. donovani
in India. India bears the burden of about half of global visceral leishmaniasis (VL) cases with emerging problems of stibanate resistance. Liposomal preparations have improved treatment outcome through shorter duration of therapy and lower toxicity compared with conventional amphotericin B. We report the efficacy of two short-course regimens of an Indian preparation of liposomal amphotericin B (Fungisome-) for VL caused by Leishmania donovani in India. An open-label, randomized, single-center comparative study was undertaken from 2008 to 2011, involving 120 treatment naive non-human immunodeficiency virus VL patients randomly allocated to two groups. Fungisome(TM) was given, in groups A (N = 60), 5 mg/kg daily for 2 days and B (N = 60), 7.5 mg/kg daily for 2 days, as intravenous infusion. Initial cure rate was 100% in both the groups after 1 month posttreatment. At 6 months after completion of treatment, definitive cure rate was group A 90% (54/60, 95% confidence interval (CI): 80.55-95.72%); group B: 100% (95% CI: 95.92-100%); (P = 0.027). No serious adverse events occurred in either group. The short-course, 2-day regimen of 15 mg/kg Fungisome(TM) infusion is easy to administer, effective, and safe for treatment of VL caused by L. donovani in India. India bears the burden of about half of global visceral leishmaniasis (VL) cases with emerging problems of stibanate resistance. Liposomal preparations have improved treatment outcome through shorter duration of therapy and lower toxicity compared with conventional amphotericin B. We report the efficacy of two short-course regimens of an Indian preparation of liposomal amphotericin B (Fungisome™) for VL caused by Leishmania donovani in India. An open-label, randomized, single-center comparative study was undertaken from 2008 to 2011, involving 120 treatment naive non-human immunodeficiency virus VL patients randomly allocated to two groups. Fungisome™ was given, in groups A (N = 60), 5 mg/kg daily for 2 days and B (N = 60), 7.5 mg/kg daily for 2 days, as intravenous infusion. Initial cure rate was 100% in both the groups after 1 month posttreatment. At 6 months after completion of treatment, definitive cure rate was group A 90% (54/60, 95% confidence interval (CI): 80.55-95.72%); group B: 100% (95% CI: 95.92-100%); (P = 0.027). No serious adverse events occurred in either group. The short-course, 2-day regimen of 15 mg/kg Fungisome™ infusion is easy to administer, effective, and safe for treatment of VL caused by L. donovani in India. |
Author | Das, Sukhen Satpati, Aditya Goswami, Rama P Rahman, Mehebubar Goswami, Rudra P |
AuthorAffiliation | Department of Tropical Medicine, Calcutta School of Tropical Medicine, West Bengal, India; Department of Rheumatology, Institution of Post Graduate Medical Education and Research, West Bengal, India; Department of Medicine, ESI Hospital, Joka, West Bengal, India |
AuthorAffiliation_xml | – name: Department of Tropical Medicine, Calcutta School of Tropical Medicine, West Bengal, India; Department of Rheumatology, Institution of Post Graduate Medical Education and Research, West Bengal, India; Department of Medicine, ESI Hospital, Joka, West Bengal, India |
Author_xml | – sequence: 1 givenname: Rama P surname: Goswami fullname: Goswami, Rama P organization: Department of Tropical Medicine, Calcutta School of Tropical Medicine, West Bengal, India; Department of Rheumatology, Institution of Post Graduate Medical Education and Research, West Bengal, India; Department of Medicine, ESI Hospital, Joka, West Bengal, India – sequence: 2 givenname: Rudra P surname: Goswami fullname: Goswami, Rudra P email: rudra.goswami@gmail.com organization: Department of Tropical Medicine, Calcutta School of Tropical Medicine, West Bengal, India; Department of Rheumatology, Institution of Post Graduate Medical Education and Research, West Bengal, India; Department of Medicine, ESI Hospital, Joka, West Bengal, India rudra.goswami@gmail.com – sequence: 3 givenname: Sukhen surname: Das fullname: Das, Sukhen organization: Department of Tropical Medicine, Calcutta School of Tropical Medicine, West Bengal, India; Department of Rheumatology, Institution of Post Graduate Medical Education and Research, West Bengal, India; Department of Medicine, ESI Hospital, Joka, West Bengal, India – sequence: 4 givenname: Aditya surname: Satpati fullname: Satpati, Aditya organization: Department of Tropical Medicine, Calcutta School of Tropical Medicine, West Bengal, India; Department of Rheumatology, Institution of Post Graduate Medical Education and Research, West Bengal, India; Department of Medicine, ESI Hospital, Joka, West Bengal, India – sequence: 5 givenname: Mehebubar surname: Rahman fullname: Rahman, Mehebubar organization: Department of Tropical Medicine, Calcutta School of Tropical Medicine, West Bengal, India; Department of Rheumatology, Institution of Post Graduate Medical Education and Research, West Bengal, India; Department of Medicine, ESI Hospital, Joka, West Bengal, India |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26526926$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkc9u1DAQxi1URLeFI1fkYzmk2I7_5YJUVhQqrQSCwtVyvJONq40dbAfEFfEkPBpPQkKXCm6cZqT5zaf55jtBRyEGQOgxJeecyeaZvSlDf055RaRQ99CKciUrKrk4QitCCKsaWatjdJLzDSFUM0ofoGMmxbzL5Ap9e9_HVKp1nFIGfJ3AlgFCwe9g5-cGxw5fha23AX_02UGye7wBn_vBBm-zz_iLLz2exwdq48eY4zBjF8PYxwLJOx_wC_w2wWiTLT4GfHY5hZ2fMfj5_cfTh-h-Z_cZHh3qKfpw-fJ6_bravHl1tb7YVI4zUirRNnTbNa0D3SkOWtda1rXcSqcXO04LJloGVLm246201GnNLdPCcsUlkPoUPb_VHad2gK2bbc52zJj8YNNXE603_06C780ufjZcUcJFPQucHQRS_DRBLmZYfrLf2wBxyoYqKRotlOL_gxLdcE4WtLpFXYo5J-juLqLELBGb3xEbys0S8cw_-dvGHf0n0_oXv2KnxQ |
CitedBy_id | crossref_primary_10_4269_ajtmh_19_0931 crossref_primary_10_1016_j_actatropica_2016_09_020 crossref_primary_10_1080_21505594_2022_2074130 crossref_primary_10_1016_j_ijpddr_2018_04_001 crossref_primary_10_1136_annrheumdis_2015_209094 crossref_primary_10_1186_s40249_016_0112_2 crossref_primary_10_3389_fbioe_2022_1016925 crossref_primary_10_1016_j_drudis_2017_09_006 crossref_primary_10_1111_jcpt_13089 crossref_primary_10_1111_tmi_12697 crossref_primary_10_1016_j_cmi_2017_11_008 |
ContentType | Journal Article |
Copyright | The American Society of Tropical Medicine and Hygiene. The American Society of Tropical Medicine and Hygiene 2016 |
Copyright_xml | – notice: The American Society of Tropical Medicine and Hygiene. – notice: The American Society of Tropical Medicine and Hygiene 2016 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7T2 7U2 C1K F1W H95 H97 L.G M7N 5PM |
DOI | 10.4269/ajtmh.14-0657 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Health and Safety Science Abstracts (Full archive) Safety Science and Risk Environmental Sciences and Pollution Management ASFA: Aquatic Sciences and Fisheries Abstracts Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality Aquatic Science & Fisheries Abstracts (ASFA) Professional Algology Mycology and Protozoology Abstracts (Microbiology C) PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic Aquatic Science & Fisheries Abstracts (ASFA) Professional Algology Mycology and Protozoology Abstracts (Microbiology C) ASFA: Aquatic Sciences and Fisheries Abstracts Health & Safety Science Abstracts Safety Science and Risk Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality Environmental Sciences and Pollution Management |
DatabaseTitleList | Aquatic Science & Fisheries Abstracts (ASFA) Professional MEDLINE - Academic MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | GOSWAMI AND OTHERS |
EISSN | 1476-1645 |
EndPage | 98 |
ExternalDocumentID | 10_4269_ajtmh_14_0657 26526926 |
Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | India |
GeographicLocations_xml | – name: India |
GroupedDBID | --- .55 .GJ 1CY 23M 2WC 34G 36B 3O- 53G 5GY 5RE 5VS 6J9 ABCQX ABPPZ ABTNK ACGFO ADBBV ADTPD AENEX AFFNX AGCDD AI. AIAGR ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW CGR CUY CVF DIK E3Z EBD EBS ECM EIF EJD EMB EMOBN F5P GX1 H13 HYE K-O KQ8 L7B MV1 NEJ NPM OHT OK1 P2P PQQKQ RHF RHI RPM SV3 TR2 TST UPT VH1 W8F WH7 WOQ WOW X7M XOL ZGI ZKB ZXP ~KM AAYXX CITATION 7X8 7T2 7U2 C1K F1W H95 H97 L.G M7N 5PM |
ID | FETCH-LOGICAL-c420t-5b91df9bce8f74e88386336d6c82652c8525b2e17cbf4b6a1c884a285a4746e03 |
IEDL.DBID | RPM |
ISSN | 0002-9637 |
IngestDate | Tue Sep 17 21:24:39 EDT 2024 Sun Sep 29 07:16:42 EDT 2024 Fri Apr 12 03:21:45 EDT 2024 Fri Aug 23 04:23:13 EDT 2024 Sat Sep 28 08:00:39 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | The American Society of Tropical Medicine and Hygiene. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c420t-5b91df9bce8f74e88386336d6c82652c8525b2e17cbf4b6a1c884a285a4746e03 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-News-1 ObjectType-Feature-3 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
OpenAccessLink | http://www.ajtmh.org/deliver/fulltext/14761645/94/1/93.pdf?itemId=%2Fcontent%2Fjournals%2F10.4269%2Fajtmh.14-0657&mimeType=pdf&containerItemId=content/journals/14761645 |
PMID | 26526926 |
PQID | 1760894404 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4710453 proquest_miscellaneous_1765985774 proquest_miscellaneous_1760894404 crossref_primary_10_4269_ajtmh_14_0657 pubmed_primary_26526926 |
PublicationCentury | 2000 |
PublicationDate | 2016-01-01 |
PublicationDateYYYYMMDD | 2016-01-01 |
PublicationDate_xml | – month: 01 year: 2016 text: 2016-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The American journal of tropical medicine and hygiene |
PublicationTitleAlternate | Am J Trop Med Hyg |
PublicationYear | 2016 |
Publisher | The American Society of Tropical Medicine and Hygiene |
Publisher_xml | – name: The American Society of Tropical Medicine and Hygiene |
References | 8124119 - BMJ. 1994 Jan 29;308(6924):307 11520836 - BMJ. 2001 Aug 25;323(7310):419-22 16772012 - Trop Med Int Health. 2006 Jun;11(6):899-905 24392168 - PLoS Negl Trop Dis. 2014;8(1):e2603 10492769 - Trans R Soc Trop Med Hyg. 1999 May-Jun;93(3):314-8 16519257 - J Postgrad Med. 2005;51 Suppl 1:S53-7 16941377 - Clin Infect Dis. 2006 Oct 1;43(7):917-24 10028069 - Clin Infect Dis. 1999 Jan;28(1):42-8; discussion 49-51 22693548 - PLoS One. 2012;7(5):e35671 19563434 - Trop Med Int Health. 2009 Aug;14(8):918-25 23167833 - Expert Opin Emerg Drugs. 2012 Dec;17(4):493-510 12955641 - Clin Infect Dis. 2003 Sep 15;37(6):800-4 19708817 - Expert Opin Emerg Drugs. 2009 Sep;14(3):395-410 24454970 - PLoS Negl Trop Dis. 2014;8(1):e2613 9615494 - Bull World Health Organ. 1998;76(1):25-32 19407109 - Am J Trop Med Hyg. 2009 May;80(5):700-3 20147716 - N Engl J Med. 2010 Feb 11;362(6):504-12 16519258 - J Postgrad Med. 2005;51 Suppl 1:S58-63 20668544 - PLoS Negl Trop Dis. 2010;4(7):e764 8783690 - Clin Infect Dis. 1996 Jun;22(6):938-43 16310148 - Lancet Infect Dis. 2005 Dec;5(12):763-74 18781879 - Clin Infect Dis. 2008 Oct 15;47(8):1000-6 20838649 - PLoS Negl Trop Dis. 2010;4(9). pii: e818. doi: 10.1371/journal.pntd.0000818 Khalil (ref23) 2014; 8 Davidson (ref8) 1996; 22 Balasegaram (ref6) 2012; 17 Sundar (ref14) 2001; 323 Sanath (ref24) 2005; 51 Meyerhoff (ref7) 1999; 28 Sundar (ref20) 2009; 80 Alvar (ref1) 2012; 7 Agrawal (ref15) 2005; 51 Sundar (ref22) 2008; 47 Singh (ref2) 2006; 11 Olliaro (ref10) 2005; 5 Rex (ref19) 2010 Meheus (ref12) 2010; 4 Burza (ref26) 2014; 8 WHO (ref11) 2010 Olliaro (ref25) 2009; 14 Bodhe (ref16) 1999; 93 Sundar (ref21) 2010; 362 Sundar (ref4) 2003; 37 (ref3) 2014 Mondal (ref17) 2010; 27 Berman (ref13) 1998; 76 den Boer (ref9) 2009; 14 Sundar (ref18) 1994; 308 Bern (ref5) 2006; 43 |
References_xml | – volume: 17 start-page: 493 year: 2012 ident: ref6 article-title: Liposomal amphotericin B as a treatment for human leishmaniasis contributor: fullname: Balasegaram – volume: 47 start-page: 1000 year: 2008 ident: ref22 article-title: New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine contributor: fullname: Sundar – volume: 11 start-page: 899 year: 2006 ident: ref2 article-title: Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India contributor: fullname: Singh – year: 2010 ident: ref19 article-title: Systemic antifungal agents contributor: fullname: Rex – volume: 28 start-page: 42 year: 1999 ident: ref7 article-title: US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis contributor: fullname: Meyerhoff – volume: 27 start-page: e764 year: 2010 ident: ref17 article-title: A curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapy contributor: fullname: Mondal – volume: 323 start-page: 419 year: 2001 ident: ref14 article-title: Treatment of Indian visceral lesihmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomized trial contributor: fullname: Sundar – volume: 8 start-page: e2613 year: 2014 ident: ref23 article-title: Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial contributor: fullname: Khalil – volume: 7 start-page: e35671 year: 2012 ident: ref1 article-title: Leishmaniasis worldwide and global estimates of its incidence contributor: fullname: Alvar – year: 2014 ident: ref3 – volume: 308 start-page: 307 year: 1994 ident: ref18 article-title: Clinicoepidemiological study of drug resistance in Indian kala-azar contributor: fullname: Sundar – volume: 51 start-page: S58 year: 2005 ident: ref24 article-title: Post-marketing study to assess the safety, tolerability and effectiveness of Fungisome: an Indian liposomal amphotericin B preparation contributor: fullname: Sanath – volume: 43 start-page: 917 year: 2006 ident: ref5 article-title: Liposomal amphotericin B for the treatment of visceral leishmaniasis contributor: fullname: Bern – volume: 14 start-page: 395 year: 2009 ident: ref9 article-title: Developments in the treatment of visceral leishmaniasis contributor: fullname: den Boer – year: 2010 ident: ref11 contributor: fullname: WHO – volume: 51 start-page: S53 year: 2005 ident: ref15 article-title: Management of visceral leishmaniasis: Indian perspective contributor: fullname: Agrawal – volume: 8 start-page: e2603 year: 2014 ident: ref26 article-title: Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India contributor: fullname: Burza – volume: 5 start-page: 763 year: 2005 ident: ref10 article-title: Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004 contributor: fullname: Olliaro – volume: 22 start-page: 938 year: 1996 ident: ref8 article-title: Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome) contributor: fullname: Davidson – volume: 362 start-page: 504 year: 2010 ident: ref21 article-title: Single-dose liposomal amphotericin B for visceral leishmaniasis in India contributor: fullname: Sundar – volume: 37 start-page: 800 year: 2003 ident: ref4 article-title: Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study contributor: fullname: Sundar – volume: 93 start-page: 314 year: 1999 ident: ref16 article-title: Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis contributor: fullname: Bodhe – volume: 4 start-page: e818 year: 2010 ident: ref12 article-title: Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent contributor: fullname: Meheus – volume: 80 start-page: 700 year: 2009 ident: ref20 article-title: Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis contributor: fullname: Sundar – volume: 76 start-page: 25 year: 1998 ident: ref13 article-title: Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries contributor: fullname: Berman – volume: 14 start-page: 918 year: 2009 ident: ref25 article-title: Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India contributor: fullname: Olliaro |
SSID | ssj0018211 |
Score | 2.2937708 |
Snippet | India bears the burden of about half of global visceral leishmaniasis (VL) cases with emerging problems of stibanate resistance. Liposomal preparations have... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 93 |
SubjectTerms | Adolescent Adult Amphotericin B - administration & dosage Amphotericin B - therapeutic use Antiprotozoal Agents - administration & dosage Antiprotozoal Agents - therapeutic use Child Child, Preschool Drug Administration Schedule Female Humans India - epidemiology Leishmania donovani Leishmaniasis, Visceral - drug therapy Leishmaniasis, Visceral - epidemiology Male Young Adult |
Title | Short-Course Treatment Regimen of Indian Visceral Leishmaniasis with an Indian Liposomal Amphotericin B Preparation (Fungisome™) |
URI | https://www.ncbi.nlm.nih.gov/pubmed/26526926 https://search.proquest.com/docview/1760894404 https://search.proquest.com/docview/1765985774 https://pubmed.ncbi.nlm.nih.gov/PMC4710453 |
Volume | 94 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELa6PSAuiJa_hVIZCSE4uBvHcWwfadWloC6qoEV7i2yv0w1qklWzfQHEk_BoPEln8lO1IHHg7Ikc-Rt5vrHH3xDyWkbBLIC2sgXnKYN4nTMjrGFGYzoR5bGR-Dh59jk9Oks-zeV8g8jhLUxbtO9dsVddlHtVsWxrK1elnwx1YpOT2QFsqMBExGRERkqIIUXvrw50zPnAecG7VCesiS82J_b7ulzC3sAg7mL3vTjF_tqoq3A7Jv1FNP-sl7wVgKYPyYOeOdL33R9ukY1QbZN7s_5u_BH58XUJVJphE7om0NOhgJx-Ceeo4E_rnH6s0Bvot6LxeBRFj0PRLFEAwzZFQ_FIlsJwb3VcrOqmLnFKQLxGTWeYiO7Tk8vQCYbXFX07hc2iALPw--evd4_J2fTw9OCI9R0WmE_iaM2kM3yRG-eDzlUStBY6FSJdpF7j2ngtY-niwJV3eeJSy73WiY21tIlK0hCJJ2SzqqvwjFDtTZIra2WsXKJEbpWTXDivXaS9EPmYvBnWOFt1QhoZJCCIS9biAklIhriMyasBgazE9bjAqt_6qsm4SiNtUNDwnzbSaAmkdkyedqjdTDfAPSbqDp43Bii1fXcEPLCV3O497vl_f_mC3Aeq1R_e7JDN9eVVeAl0Zu12yejDnO-2TnwN7N34WQ |
link.rule.ids | 230,315,733,786,790,891,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgEX3o_laSSE4JDdJI5j-wgVqy3sVhVsq96i2OuwgSZZNdkLR8Qv4afxS5jZJFVbJCQ4eyI7nrHnG3v8DcAL4Tu9QNjqLYIg9tBfZ57mqfa0onDCz0It6HHybC-eHETvj8TRFoj-Lcwmad-afFgeF8MyX25yK1eFHfV5YqP92Q5uqIhE-OgSXMb1Goo-SO8uD1QYBD3qRfuSLbUmvdkcpV-aYom7g4eel-rvhTFV2CZmhbNe6Q-oeTFj8owLGt-Aw37wbebJ1-G6MUP77QKv4z__3U243oFS9qZtvgVbrrwNV2bdtfsd-P5piSjdo_p2tWPzPjedfXSfqTgAqzK2W5KhscO8tnTKxaYur5fErZHWec3otJdhcyc1zVdVXRXUJRpTRXTR2BF7y_ZPXMtFXpXs1Rj3oRzF3K8fP1_fhYPxu_nOxOuKN3g2Cv3GE0YHi0wb61QmI6cUVzHn8SK2iibdKhEKE7pAWpNFJk4Dq1SUhkqkkYxi5_N7sF1WpXsATFkdZTJNRShNJHmWSiMCbqwyvrKcZwN42SsvWbUcHQnGNqTwZKNwjG8SUvgAnveqTQqaj2NKKK7WdRLI2FeauBL_KiO0EoiXB3C_NYfT7no7GoA8ZyinAsTifb4F1b9h8-7U_fC_v3wGVyfz2TSZ7u59eATXENF1Z0SPYbs5WbsniJoa83SzRn4DqQUZZQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSBUX3o_laSSE4JDNw3FsH6GwamG3WkGLKi5R7NhsoElWTfbCEfFL-Gn8EmY2SbUtEoeePZZlz9jzjT3-hpDnPLAqB9jq5WGYeOCvnadYpjwlMZwIXKQ4fk6e7Se7h_H7I360UeprnbRvdDGujstxVSzWuZXL0vhDnpg_n-3AgQpIhPnL3PmXyRXYs5EYAvX-AUFGYTggX7Ax0dFr4r9NP_vWlgs4ITzwvliDL0qwyjayK2x6pn_g5vmsyQ03NLlOvgwT6LJPvo9XrR6bH-e4HS80wxvkWg9O6etO5Ca5ZKtbZHvWP7_fJj8_LQCte1jnrrH0YMhRpx_tVywSQGtH9yo0OPq5aAzedtGpLZoFcmxkTdFQvPWl0NxLTYtl3dQlDglGVSNtNAxE39D5ie04yeuKvpzAeVSAmP3z6_erO-Rw8u5gZ9frizh4Jo6C1uNahblT2ljpRGylZDJhLMkTI3HhjeQR15ENhdEu1kkWGinjLJI8i0Wc2IDdJVtVXdn7hEqjYieyjEdCx4K5TGgeMm2kDqRhzI3Ii0GB6bLj6kghxkGlp2ulQ5yTotJH5Nmg3rTE9TjGxOJ61aShSAKpkDPxvzJcSQ64eUTudSZxOtxgSyMizhjLqQCyeZ9tARNYs3r3Kn9w4Z5Pyfb87SSd7u1_eEiuArDrr4oeka32ZGUfA3hq9ZP1NvkLXMMb5Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Short-Course+Treatment+Regimen+of+Indian+Visceral+Leishmaniasis+with+an+Indian+Liposomal+Amphotericin+B+Preparation+%28Fungisome%E2%84%A2%29&rft.jtitle=The+American+journal+of+tropical+medicine+and+hygiene&rft.au=Goswami%2C+Rama+P.&rft.au=Goswami%2C+Rudra+P.&rft.au=Das%2C+Sukhen&rft.au=Satpati%2C+Aditya&rft.date=2016-01-01&rft.issn=0002-9637&rft.eissn=1476-1645&rft.volume=94&rft.issue=1&rft.spage=93&rft.epage=98&rft_id=info:doi/10.4269%2Fajtmh.14-0657&rft.externalDBID=n%2Fa&rft.externalDocID=10_4269_ajtmh_14_0657 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-9637&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-9637&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-9637&client=summon |